Skip to main content
ZEVRA THERAPEUTICS, INC. logo

ZEVRA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ZVRA ISIN · US4884452065 LEI · 254900CU6T74V18Y1W18 US Manufacturing
Open in API
Filings indexed 830 across all filing types
Latest filing 2021-06-24 Declaration of Voting R…
Country US United States of America
Listing US ZVRA

About ZEVRA THERAPEUTICS, INC.

https://zevra.com/

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for patients with rare diseases. The company focuses on addressing significant unmet medical needs by combining a data-driven scientific approach with a patient-first perspective. Its portfolio includes commercial products such as MIPLYFFA®, an FDA-approved treatment for Niemann-Pick disease type C (NPC), and OLPRUVA®. Zevra Therapeutics also maintains a late-stage clinical pipeline, specializing in advancing promising medicines that face complex clinical and regulatory challenges for conditions with limited or no available treatments.

Recent filings

Filing Released Lang Actions
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filing with the SEC, dated June 24, 2021, reporting on the results of the 2021 Annual Meeting of Stockholders of KemPharm, Inc. It details the submission of matters to a vote of security holders, including election of directors, ratification of auditors, advisory votes on executive compensation, and approval of stock plans. The content focuses on official voting results from the annual meeting. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document is not a full annual report, proxy statement, or management discussion, but specifically the official voting results. The length (5929 characters) and detailed vote counts confirm it is the voting results announcement, not just a brief notice or proxy solicitation. Therefore, the correct classification is DVA with high confidence.
2021-06-24 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on the issuance of warrants, amendments to the articles of incorporation eliminating certain preferred stock series, and related agreements. There are no financial statements or detailed financial performance data presented, nor is this a full annual or quarterly report. The document is not a transcript, proxy, or governance report. It primarily announces a capital raising transaction and related corporate actions. Therefore, it fits best under Capital/Financing Update (CAP). The document length and detail confirm it is a substantive filing, not just a brief announcement or certification.
2021-06-23 English
Regulatory Filings 2021
Regulatory Filings
2021-06-22 English
FORM 4
Director's Dealing
2021-06-21 English
FORM 4
Director's Dealing
2021-06-21 English
FORM 4
Director's Dealing
2021-06-21 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.